NCT04992312View on ClinicalTrials.gov

A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

March 24, 2022

Primary Completion Date

November 5, 2023

Study Completion Date

November 5, 2023

Conditions
Type 1 Diabetes
Interventions
DRUG

Glucagon Nasal Powder [Baqsimi]

Administered intranasally

Trial Locations (8)

14203

UBMD Pediatrics, Buffalo

19104

Children's Hospital of Philadelphia, Philadelphia

32207

Nemours Childrens Clinic, Jacksonville

45229

Cincinnati Childrens Hospital Medical Center, Cincinnati

46202

Riley Hospital for Children, Indianapolis

55454

University of Minnesota Medical School, Minneapolis

64108

Children's Mercy Hospital, Kansas City

83712

St. Luke's Regional Medical Center, Boise

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY